Background
Mary and Walter Vermedahl, experienced ropers, purchased a horse named Charlie from Daniel and Toni Heath for $50,000 on January 11, 2022. The Heaths advertised Charlie as a “Champion Reined Cow Horse” and “Roping Head Horse” suitable for Mary’s intended use in competitive team roping. Mary evaluated Charlie extensively before purchase: she rode him on January 8 and 9 under live-cattle conditions without incident, and Dr. Buchanan performed a prepurchase examination on the morning of sale, finding Charlie “sound baseline” with minor soreness on flexion—which Mary acknowledged as typical for an eight-year-old rope horse.
Within hours of bringing Charlie home on January 11, Mary observed abnormal behavior she believed indicated pain. On January 12, Dr. Strosnider examined Charlie and observed lameness, including a noticeable head bob and left-front tendinitis. On January 14, Dr. Kaufman examined Charlie, found him lame and not rideable, and ordered blood tests. The tests revealed lidocaine and its metabolite at concentrations far exceeding therapeutic thresholds (9.05 μg/ml of lidocaine and 2.55 ng/ml of 3-Hydroxylidocaine)—neither substance occurs naturally in horses. The Vermedahls sued, claiming the Heaths sold them a lame horse and administered lidocaine to mask its condition. The Heaths counterclaimed for defamation, alleging the Vermedahls falsely told others that Daniel had drugged Charlie. The trial court excluded the Vermedahls’ expert testimony entirely and granted summary judgment to the Heaths on all claims.
The Court’s Holding
The Arizona Court of Appeals reversed both summary judgments, holding that the trial court erred by excluding expert testimony wholesale and by resolving genuinely disputed factual questions at summary judgment rather than submitting them to a jury. The court affirmed that Dr. Kaufman (an equine veterinarian with 50+ years of experience) and Ms. Mahoney (a toxicology expert) were qualified and their opinions relevant. However, the trial court improperly excluded their entire testimony because portions were speculative about timing and dosage. The court held that the experts’ testimony about laboratory findings, the non-natural presence of lidocaine, the elevated concentrations exceeding therapeutic thresholds, and the clinical significance of those results were admissible and did not depend on speculation. Ms. Mahoney’s toxicology testimony—explaining how she detected and quantified lidocaine—was factual, not speculative. Dr. Kaufman’s clinical observations and his explanation that lidocaine masks lameness by suppressing observable symptoms were relevant to whether Charlie’s apparent soundness at the PPE could reflect a drugged condition.
On the merits, the court found genuine disputes of material fact precluding summary judgment. The critical dispute centered on whether lidocaine administered before the January 11 PPE could remain detectable in Charlie’s blood on January 14. The Vermedahls relied on USEF Guidelines stating lidocaine may be detectable for up to seven days depending on dosage, route, and individual factors. The Heaths relied on RMTC and FEI materials suggesting a 48–72 hour detection window. Critically, the RMTC study itself cautioned that detectability varies depending on dose, frequency, route, and horse physiology, making it a fact question unsuitable for summary judgment. Evidence also conflicted on Charlie’s condition: while he appeared sound during test rides and the PPE, the Vermedahls presented evidence of rapid deterioration within hours (uneven weight distribution, spasms, lameness) and Dr. Strosnider’s findings of lameness and tendinitis—a condition previously undisclosed. The court held this constellation of competing inferences must reach a jury.
Regarding the defamation counterclaim, the trial court erred in finding “no evidence” of publication. Mary admittedly told Tyler Merrill and her daughter Amber that Charlie was lame and had lidocaine in his blood, and Amber discussed these matters within the western performance horse community. The statements could reasonably be interpreted as implying the Heaths sold a drugged or misrepresented horse—an assertion capable of harming Daniel in his trade as a breeder. The Vermedahls’ invocation of conditional privilege presented a fact-intensive question unsuitable for resolution at summary judgment. Because statements imply wrongdoing in Daniel’s profession, they constitute potential defamation per se, requiring no proof of specific damages—only publication, which the record established.
Key Takeaways
- Trial courts must not exclude an expert’s entire testimony when portions are inadmissible; distinguishing between speculative and reliable opinions is necessary, with admissible portions reaching the jury.
- The gatekeeping function under Arizona Rule of Evidence 702 does not replace the adversary system; cross-examination, contrary evidence, and jury instructions are the proper means to attack weak evidence.
- Conflicting scientific evidence about drug detection times and pharmacological effects must go to a jury, not be resolved at summary judgment based on the trial judge’s preference.
- Statements implying dishonest business practices in someone’s profession (here, selling a drugged horse) can be actionable as defamation per se, presuming damages without separate proof of harm.
- Conditional privilege against defamation is fact-dependent and typically unsuitable for resolution on summary judgment when the speaker communicated to persons beyond dispute resolution.
Why It Matters
This decision clarifies the limits of expert evidence gatekeeping in Arizona. While trial courts must screen for reliability, they cannot use Rule 702 to remove admissible testimony merely because some related opinions are speculative. The ruling reinforces that detailed factual and laboratory testimony—here, actual toxicology results and their significance—is distinguishable from opinions about timing or causation and should reach the jury. This has broad implications for veterinary, pharmaceutical, and forensic cases where scientific evidence may be complex but factually grounded.
The decision also illustrates that competing scientific guidance documents (USEF vs. RMTC vs. FEI) reflecting different testing standards and acknowledging variability are not dispositive at summary judgment. When both materials recognize that outcomes depend on circumstances, a jury must weigh which authority or interpretation is more credible. Additionally, the defamation holding confirms that statements implying a professional engaged in fraud or deception can harm trade and reputation, making them per se actionable even if the speaker subjectively believed them true based on subsequent testing—a question of truth itself becomes fact for the jury.